8-K: scPharmaceuticals Reports Strong Q1 2025 Revenue Growth Driven by FUROSCIX

scPharmaceuticals announced a 93% increase in FUROSCIX revenue for Q1 2025, driven by expanded indications and increased prescription fills.

Summary

• scPharmaceuticals reported its Q1 2025 financial results, highlighting significant growth in FUROSCIX revenue.
• Net FUROSCIX revenue reached $11.8 million, a 93% increase compared to $6.1 million in Q1 2024.
• The company saw a 73% increase in FUROSCIX doses filled, with approximately 13,900 doses in Q1 2025 compared to 8,000 in Q1 2024.
• Sales to Integrated Delivery Networks increased by 119% compared to the fourth quarter of 2024.
• The gross-to-net (GTN) discount was 23% for Q1 2025, compared to 19% for Q4 2024.
• scPharmaceuticals formally launched FUROSCIX in the second approved indication, Chronic Kidney Disease (CKD), in April 2025.
• The company is targeting an sNDA submission for the 80mg/1mL FUROSCIX Autoinjector in Q3 2025.
• The net loss for Q1 2025 was $19.7 million, compared to a net loss of $14.1 million in Q1 2024.
• As of March 31, 2025, scPharmaceuticals had $57.5 million in cash and cash equivalents.
• Total shares outstanding as of March 31, 2025, were 50,283,925.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to strong revenue growth and expansion into new markets, but tempered by increased net losses and operating expenses. The company's future outlook is optimistic, but risks remain.

Positives

• Significant revenue growth for FUROSCIX, indicating increasing market adoption.
• Successful expansion of FUROSCIX indication to include Chronic Kidney Disease (CKD).
• Progress on the development of the FUROSCIX Autoinjector, with sNDA submission targeted for Q3 2025.
• Increase in sales to Integrated Delivery Networks, suggesting stronger partnerships and distribution channels.
• Increase in filled prescriptions due to Medicare-covered patients reaching their annual out-of-pocket maximum or signing up for Part D smoothing.

Negatives

• Increased net loss of $19.7 million for Q1 2025 compared to $14.1 million for Q1 2024.
• Increase in operating expenses, including cost of product revenues, research and development, and selling, general and administrative expenses.
• Decrease in cash and cash equivalents from $75.7 million at the end of 2024 to $57.5 million as of March 31, 2025.
• Increased gross-to-net (GTN) discount from 19% to 23%, impacting net revenue.

Risks

• Dependence on the commercial success of FUROSCIX.
• Risks related to obtaining regulatory approval for product candidates.
• Potential difficulties in manufacturing sufficient product for commercialization.
• History of operating losses and the expectation of increasing losses in the future.
• Need for additional funding and the risk of being unable to raise capital when needed.
• Restrictions on operating and financial flexibility due to the terms of the credit facility and revenue participation financing facility.
• Uncertainty in clinical and preclinical development outcomes.
• Impact of global economic factors and uncertainties on the company's operations.

Future Outlook

The company expects a favorable tailwind supporting FUROSCIX growth through Q2 and the balance of 2025 due to the reduction in cost burden for Medicare-covered patients.

Management Comments

• The FUROSCIX indication expansion into chronic kidney disease (CKD) represents encouraging progress towards accomplishing scPharmaceuticals long-term growth initiatives for the products lifecycle.
• Our sales force is in the field calling on nephrologists and we are pleased with the receptivity towards FUROSCIX from these physicians.
• Starting in March and in the first half of Q2, we have seen an increase in the number of Medicare-covered patients who have reached their annual out-of-pocket maximum or have signed up for Part D smoothing.
• Historically, the reduction in cost burden to patients has been associated with a meaningful rise in FUROSCIX filled prescription volumes.
• As a result, in Q2, we have seen a corresponding acceleration in our fill rate, prescriptions written and in units shipped to patients.
• We view this trend as a favorable tailwind that we expect will support FUROSCIX growth through Q2 and for the balance of 2025.

Industry Context

The expansion into the CKD market aligns with the broader trend of pharmaceutical companies seeking to address chronic diseases with innovative treatment options. The autoinjector program reflects a focus on patient convenience and adherence, which is increasingly important in the competitive pharmaceutical landscape.

Comparison to Industry Standards

• Comparing scPharmaceuticals' revenue growth to companies like Ardelyx, which also focuses on cardiorenal diseases, provides context.
• Ardelyx reported total revenues of $13.4 million for the first quarter of 2024, a 40% increase compared to the first quarter of 2023.
• scPharmaceuticals' 93% growth in FUROSCIX revenue significantly outpaces Ardelyx's growth rate, suggesting a stronger market penetration for FUROSCIX.
• However, Ardelyx's total revenue is higher, indicating a broader product portfolio.
• Similarly, comparing scPharmaceuticals' autoinjector program to companies like Amgen, which has experience with autoinjector devices, highlights the potential for improved patient outcomes and market adoption.
• Amgen's Neulasta Onpro autoinjector has demonstrated improved patient adherence and reduced healthcare costs, suggesting that scPharmaceuticals' autoinjector could achieve similar benefits.

Stakeholder Impact

• Shareholders may be encouraged by the strong revenue growth, but concerned about the increased net loss.
• Patients with chronic heart failure or chronic kidney disease may benefit from the expanded availability of FUROSCIX and the potential for a more convenient autoinjector.
• Employees may see increased job security and growth opportunities due to the company's expansion.
• Healthcare providers may have a new treatment option for managing edema in patients with chronic conditions.

Next Steps

• Submission of sNDA for the 80mg/1mL FUROSCIX Autoinjector in Q3 2025.
• Continued commercialization of FUROSCIX in both chronic heart failure and chronic kidney disease indications.
• Ongoing efforts to expand sales and distribution channels, including Integrated Delivery Networks.
• Monitoring and managing gross-to-net (GTN) discounts to optimize net revenue.

Key Dates

Keywords

FUROSCIX, scPharmaceuticals, Chronic Kidney Disease, Autoinjector, Revenue, Financial Results, Cardiorenal, Edema